Avantor® Reports Second Quarter 2025 Results

Core Viewpoint - Avantor, Inc. reported its financial results for the second fiscal quarter ended June 30, 2025, highlighting a focus on growth, operational leverage, and disciplined execution despite facing challenges in certain segments [1][2]. Financial Performance - Net sales for the second quarter were $1,683.4 million, a decrease of 1% compared to the same period in 2024, with foreign currency translation positively impacting sales by 2% and M&A negatively impacting by 3%, resulting in flat organic sales [3][7]. - Net income decreased to $64.7 million from $92.9 million in the second quarter of 2024, with adjusted net income at $161.2 million compared to $168.0 million in the prior year [4][7]. - Adjusted EBITDA was $279.8 million, with an adjusted EBITDA margin of 16.6% [4][7]. Segment Results - The Laboratory Solutions segment reported net sales of $1,122.1 million, a decrease of 3% year-over-year, with an adjusted operating income of $133.3 million and a margin of 11.9% [8][30]. - The Bioscience Production segment saw net sales of $561.3 million, an increase of 3% compared to the previous year, with an adjusted operating income of $139.7 million and a margin of 24.9% [8][30]. Cash Flow and Leverage - Operating cash flow was $154.4 million, while free cash flow was $125.4 million, with adjusted net leverage at 3.2x as of June 30, 2025 [5][29]. Leadership Transition - Avantor announced the appointment of Emmanuel Ligner as the new President and CEO, effective August 18, 2025, succeeding Michael Stubblefield [9].